A summary of recent clinical trial news.
The study Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice by Taro Pharmaceuticals has been updated with results.
The key finding is that the 0.5% Malathion gel eradicated lice in 83% of patricipants, versus 63% for 1% Nix Creme Rinse (n = 47, p = 0.04).
The study Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice by Taro Pharmaceuticals has been updated with results.
The key finding is that 0.5% malathion gel resulted in clinical evidence of cholinesterase inhibition in two-thirds of participants immediately after treatment, but that this had disappeared after 24 hours. All head lice infection was eradicated after 14 days from treatment (n = 12, no statistical analysis provided).
The study Pediatric Head Lice Study Product Comparison by Hackensack University Medical Center has been completed.
The study tested the safety and efficacy of 100% Dimethicone Pediculocide in School-Age Children against several standard head lice products (n = 98). Results will be reported when published.
The study Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation by Hatchtech Pty has been marked as recruiting.
The study expects to test around 50 participants in the coming months.
The study Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation by Hatchtech Pty has been marked as ongoing.
The study is currently testing around 380 participants for the tolerability, safety and efficacy of 0.74% Abametapir lotion.